Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus

References

• Pons-Estel, G. J., G. S. Alarcon, L. Scofield, et al. 2010. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 39: 257–268
   PubMed Web of Science ®Google Scholar
• Stahl-Hallengren, C., A. Jonsen, O. Nived, and G. Sturfelt. 2000. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J. Rheumatol. 27: 685–691
   PubMed Web of Science ®Google Scholar
• Merrell, M., and L. E. Shulman. 1955. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J. Chronic Dis. 1: 12–32
   PubMedGoogle Scholar
• Kasitanon, N., L. S. Magder, and M. Petri. 2006. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 85: 147–156
   PubMed Web of Science ®Google Scholar
• Funauchi, M., H. Shimadzu, C. Tamaki, et al. 2007. Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus: results from a single center. Rheumatol. Int. 27: 243–249
   PubMed Web of Science ®Google Scholar
• Urowitz, M. B., D. D. Gladman, B. D. Tom, et al. 2008. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J. Rheumatol. 35: 2152–2158
   PubMed Web of Science ®Google Scholar
• Gustafsson, J., J. F. Simard, I. Gunnarsson, et al. 2012. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res. Ther. 14: R46
   PubMed Web of Science ®Google Scholar
• Bernatsky, S., J. F. Boivin, L. Joseph, et al. 2006. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54: 2550–2557
   PubMed Web of Science ®Google Scholar
• Jacobsen, S., J. Petersen, S. Ullman, et al. 1998. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin. Rheumatol. 17: 478–484
   PubMed Web of Science ®Google Scholar
• Chambers, S. A., E. Allen, A. Rahman, and D. Isenberg. 2009. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 48: 673–675
   PubMed Web of Science ®Google Scholar
• Rabbani, M. A., H. B. Habib, M. Islam, et al. 2009. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. Lupus 18: 848–855
   PubMed Web of Science ®Google Scholar
• Wadee, S., M. Tikly, and M. Hopley. 2007. Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology (Oxford) 46: 1487–1491
   PubMed Web of Science ®Google Scholar
• Bjornadal, L., L. Yin, F. Granath, et al. 2004. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J. Rheumatol. 31: 713–719
   PubMed Web of Science ®Google Scholar
• Voss, A., H. Laustrup, J. Hjelmborg, and P. Junker. 2013. Survival in systemic lupus erythematosus, 1995–2010. A prospective study in a Danish community. Lupus 22: 1185–1191
   PubMed Web of Science ®Google Scholar
• Esdaile, J. M., M. Abrahamowicz, T. Grodzicky, et al. 2001. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44: 2331–2337
   PubMed Web of Science ®Google Scholar
• Hak, A. E., E. W. Karlson, D. Feskanich, et al. 2009. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum. 61: 1396–1402
   PubMed Web of Science ®Google Scholar
• Gustafsson, J., I. Gunnarsson, O. Borjesson, et al. 2009. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus -- a prospective cohort study. Arthritis Res. Ther. 11: R186
   PubMed Web of Science ®Google Scholar
• Bengtsson, C., M. L. Ohman, O. Nived, and S. Rantapaa Dahlqvist. 2011. Cardiovascular event in systemic lupus erythematosus in northern Sweden – incidence and predictors in a 7-year follow up study. Lupus 21: 452--459
   PubMedGoogle Scholar
• Roman, M. J., B. A. Shanker, A. Davis, et al. 2003. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349: 2399–2406
   PubMed Web of Science ®Google Scholar
• McMahon, M., B. J. Skaggs, L. Sahakian, et al. 2011. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann. Rheum. Dis. 70: 1619–1624
   PubMed Web of Science ®Google Scholar
• Asanuma, Y., A. Oeser, A. K. Shintani, et al. 2003. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349: 2407–2415
   PubMed Web of Science ®Google Scholar
• Kao, A. H., M. C. Wasko, S. Krishnaswami, et al. 2008. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am. J. Cardiol. 102: 755–760
   PubMedGoogle Scholar
• Peters, S. A., D. E. Grobbee, and M. L. Bots. 2011. Carotid intima-media thickness: a suitable alternative for cardiovascular risk as outcome? Eur. J. Cardiovasc. Prev. Rehabil. 18: 167–174
   PubMed Web of Science ®Google Scholar
• de Leeuw, K., A. J. Smit, E. de Groot, et al. 2009. Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. Atherosclerosis 206: 546–550
   PubMed Web of Science ®Google Scholar
• Hillen, T., R. Nieczaj, H. Munzberg, et al. 2000. Carotid atherosclerosis, vascular risk profile and mortality in a population-based sample of functionally healthy elderly subjects: the Berlin ageing study. J. Intern. Med. 247: 679–688
   PubMed Web of Science ®Google Scholar
• Manzi, S., E. N. Meilahn, J. E. Rairie, et al. 1997. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145: 408–415
   PubMed Web of Science ®Google Scholar
• Urowitz, M. B., D. Ibanez, and D. D. Gladman. 2007. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J. Rheumatol. 34: 70–75
   PubMed Web of Science ®Google Scholar
• Petri, M., S. Perez-Gutthann, D. Spence, and M. C. Hochberg. 1992. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am. J. Med. 93: 513–519
   PubMed Web of Science ®Google Scholar
• Svenungsson, E., J. Gustafsson, D. Leonard, et al. 2009. A STAT4 risk allele is associated with ischemic cerebrovascular events and antiphospholipid antibodies in systemic lupus erythematosus. Ann. Rheum. Dis. 69: 834--840
   PubMed Web of Science ®Google Scholar
• Jonsson, H., O. Nived, and G. Sturfelt. 1989. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 68: 141–150
   PubMed Web of Science ®Google Scholar
• Bessant, R., A. Hingorani, L. Patel, et al. 2004. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 43: 924–929
   PubMed Web of Science ®Google Scholar
• Magder, L. S., and M. Petri. 2012. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am. J. Epidemiol. 176: 708–719
   PubMed Web of Science ®Google Scholar
• Ward, M. M. (1999. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42: 338–346
   PubMed Web of Science ®Google Scholar
• Manzi, S., F. Selzer, K. Sutton-Tyrrell, et al. 1999. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42: 51–60
   PubMed Web of Science ®Google Scholar
• Bruce, I. N., R. J. Burns, D. D. Gladman, and M. B. Urowitz. 2000. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J. Rheumatol. 27: 2372–2377
   PubMed Web of Science ®Google Scholar
• Kiani, A. N., W. S. Post, L. S. Magder, and M. Petri. 2011. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford). 50: 2071--2079
   PubMed Web of Science ®Google Scholar
• Huang, Y. L., H. T. Chung, C. J. Chang, et al. 2009. Lymphopenia is a risk factor in the progression of carotid intima-media thickness in juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 60: 3766–3775
   PubMedGoogle Scholar
• Roman, M. J., M. K. Crow, M. D. Lockshin, et al. 2007. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 56: 3412–3419
   PubMed Web of Science ®Google Scholar
• Rua-Figueroa, I., O. Arencibia-Mireles, M. Elvira, et al. 2010. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. Ann. Rheum. Dis. 69: 1136–1139
   PubMedGoogle Scholar
• Thompson, T., K. Sutton-Tyrrell, R. P. Wildman, et al. 2008. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum. 58: 835–842
   PubMedGoogle Scholar
• Hodis, H. N., W. J. Mack, L. LaBree, et al. 1998. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 128: 262–269
   PubMed Web of Science ®Google Scholar
• Kao A. H., A. Lertratanakul, J. R. Elliott, et al. 2013. Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. Am J Cardiol. 2: 117–121
   Google Scholar
• Pons-Estel, G. J., L. A. Gonzalez, J. Zhang, et al. 2009. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford) 48: 817–822
   PubMed Web of Science ®Google Scholar
• Haque, S., C. Gordon, D. Isenberg, et al. 2010. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J. Rheumatol. 37: 322–329
   PubMed Web of Science ®Google Scholar
• Petri, M., S. Perez-Gutthann, D. Spence, and M. C. Hochberg. 1992. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am. J. Med. 93: 513–519
   PubMed Web of Science ®Google Scholar
• Maksimowicz-McKinnon, K., L. S. Magder, and M. Petri. 2006. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J. Rheumatol. 33: 2458–2463
   PubMed Web of Science ®Google Scholar
• McMahon, M., J. Grossman, B. Skaggs, et al. 2009. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 60: 2428–2437
   PubMed Web of Science ®Google Scholar
• Toloza, S. M., A. G. Uribe, G. McGwin, Jr et al. 2004. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 50: 3947–3957
   PubMed Web of Science ®Google Scholar
• Manger, K., M. Kusus, C. Forster, et al. 2003. Factors associated with coronary artery calcification in young female patients with SLE. Ann. Rheum. Dis. 62: 846–850
   PubMed Web of Science ®Google Scholar
• Ahmad, Y., J. Shelmerdine, H. Bodill, et al. 2007. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 46: 983–988
   PubMed Web of Science ®Google Scholar
• Arnson, Y., Y. Shoenfeld, and H. Amital. 2010. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J. Autoimmun. 34: J258–J265
   PubMed Web of Science ®Google Scholar
• Klareskog, L., L. Padyukov, and L. Alfredsson. 2007. Smoking as a trigger for inflammatory rheumatic diseases. Curr. Opin. Rheumatol. 19: 49–54
   PubMed Web of Science ®Google Scholar
• Costenbader, K. H., and E. W. Karlson. 2005. Cigarette smoking and systemic lupus erythematosus: a smoking gun? Autoimmunity 38: 541–547
   PubMed Web of Science ®Google Scholar
• Gustafsson J. T., I. G. Susanne Pettersson, A. Zickert, et al. 2012. Cigarette smoking and antiphospholipid antibodies in systemic lupus erythematosus. Abstract EULAR. Available from: www.abstracts2view/com/eular
   Google Scholar
• Freemer, M. M., T. E. King, Jrand L. A. Criswell. 2006. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann. Rheum. Dis. 65: 581–584
   PubMed Web of Science ®Google Scholar
• Borba, E. F., and E. Bonfa. 1997. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6: 533–539
   PubMed Web of Science ®Google Scholar
• Borba, E. F., E. Bonfa, C. G. Vinagre, et al. 2000. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum. 43: 1033–1040
   PubMedGoogle Scholar
• de Carvalho, J. F., E. F. Borba, V. S. Viana, et al. 2004. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum. 50: 3610–3615
   PubMedGoogle Scholar
• Dinu, A. R., J. T. Merrill, C. Shen, et al. 1998. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7: 355–360
   PubMed Web of Science ®Google Scholar
• Svenungsson, E., G. Z. Fei, K. Jensen-Urstad, et al. 2003. TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 12: 454–461
   PubMed Web of Science ®Google Scholar
• Asanuma, Y., C. P. Chung, A. Oeser, et al. 2006. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J. Rheumatol. 33: 539–545
   PubMed Web of Science ®Google Scholar
• Appel, G. B., C. B. Blum, S. Chien, et al. 1985. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N. Engl. J. Med. 312: 1544–1548
   PubMed Web of Science ®Google Scholar
• Petri, M., C. Lakatta, L. Magder, and D. Goldman. 1994. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am. J. Med. 96: 254–259
   PubMed Web of Science ®Google Scholar
• Borba, E. F., and E. Bonfa. 2001. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol. 28: 780–785
   PubMed Web of Science ®Google Scholar
• Hahn, B. H., J. Grossman, B. J. Ansell, et al. 2008. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 10: 213
   PubMed Web of Science ®Google Scholar
• McMahon, M., J. Grossman, J. FitzGerald, et al. 2006. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54: 2541–2549
   PubMed Web of Science ®Google Scholar
• Frostegard, J., E. Svenungsson, R. Wu, et al. 2005. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 52: 192--200
   PubMed Web of Science ®Google Scholar
• Wu, R., U. de Faire, C. Lemne, et al. 1999. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33: 53–59
   PubMed Web of Science ®Google Scholar
• Svenungsson, E., K. Jensen-Urstad, M. Heimburger, et al. 2001. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104: 1887–1893
   PubMed Web of Science ®Google Scholar
• Doria, A., Y. Shoenfeld, R. Wu, et al. 2003. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 62: 1071–1077
   PubMed Web of Science ®Google Scholar
• Vaarala, O., G. Alfthan, M. Jauhiainen, et al. 1993. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341: 923–925
   PubMed Web of Science ®Google Scholar
• Romero, F. I., O. Amengual, T. Atsumi, et al. 1998. Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br. J. Rheumatol. 37: 883–888
   PubMedGoogle Scholar
• Hayem, G., P. Nicaise-Roland, E. Palazzo, et al. 2001. Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 10: 346–351
   PubMed Web of Science ®Google Scholar
• Ho, K. T., C. W. Ahn, G. S. Alarcon, et al. 2005. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 44: 1303–1307
   PubMed Web of Science ®Google Scholar
• Celermajer, D. S., K. E. Sorensen, V. M. Gooch, et al. 1992. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340: 1111–1115
   PubMed Web of Science ®Google Scholar
• Lima, D. S., E. I. Sato, V. C. Lima, et al. 2002. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J. Rheumatol. 29: 292–297
   PubMed Web of Science ®Google Scholar
• El-Magadmi, M., H. Bodill, Y. Ahmad, et al. 2004. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 110: 399–404
   PubMed Web of Science ®Google Scholar
• Kiss, E., P. Soltesz, H. Der, et al. 2006. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J. Autoimmun. 27: 211–217
   PubMed Web of Science ®Google Scholar
• Svenungsson, E., A. Cederholm, K. Jensen-Urstad, et al. 2008. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand. J. Rheumatol. 37: 352–359
   PubMed Web of Science ®Google Scholar
• Mak, A., Y. Liu, and R. C. Ho. 2011. Endothelium-dependent but not endothelium-independent flow-mediated dilation is significantly reduced in patients with systemic lupus erythematosus without vascular events: a metaanalysis and metaregression. J. Rheumatol. 38: 1296–1303
   PubMedGoogle Scholar
• Leonard, D., T. Akhter, G. Nordmark, et al. 2011. Increased carotid intima thickness and decreased media thickness in premenopausal women with systemic lupus erythematosus: an investigation by non-invasive high-frequency ultrasound. Scand. J. Rheumatol. 40: 279–282
   PubMed Web of Science ®Google Scholar
• Spronk, P. E., H. Bootsma, M. G. Huitema, et al. 1994. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin. Exp. Immunol. 97: 439–444
   PubMed Web of Science ®Google Scholar
• Rho, Y. H., C. P. Chung, A. Oeser, et al. 2008. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J. Rheumatol. 35: 1789–1794
   PubMed Web of Science ®Google Scholar
• Colombo, B. M., F. Cacciapaglia, M. Puntoni, et al. 2009. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun. Rev. 8: 309–315
   PubMed Web of Science ®Google Scholar
• de Leeuw, K., B. Freire, A. J. Smit, et al. 2006. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 15: 675–682
   PubMed Web of Science ®Google Scholar
• Reynolds, H. R., J. Buyon, M. Kim, et al. 2010. Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis 210: 569–574
   PubMed Web of Science ®Google Scholar
• Blankenberg, S., S. Barbaux, and L. Tiret. 2003. Adhesion molecules and atherosclerosis. Atherosclerosis 170: 191–203
   PubMed Web of Science ®Google Scholar
• Ikeda, Y., T. Fujimoto, M. Ameno, et al. 1998. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. Lupus 7: 347–354
   PubMedGoogle Scholar
• Spiel, A. O., J. C. Gilbert, and B. Jilma. 2008. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 117: 1449–1459
   PubMed Web of Science ®Google Scholar
• Lai, K. N., J. C. Leung, K. B. Lai, et al. 1996. Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies. Ann. Rheum. Dis. 55: 57–62
   PubMed Web of Science ®Google Scholar
• Ridker, P. M., S. S. Bassuk, and P. P. Toth. 2003. C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr. Atheroscler. Rep. 5: 341–349
   PubMedGoogle Scholar
• Blake, G. J., and P. M. Ridker. 2002. Inflammatory bio-markers and cardiovascular risk prediction. J. Intern. Med. 252: 283–294
   PubMed Web of Science ®Google Scholar
• Danesh, J., S. Lewington, S. G. Thompson, et al. 2005. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294: 1799–1809
   PubMed Web of Science ®Google Scholar
• Kiani, A. N., L. Magder, and M. Petri. 2008. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J. Rheumatol. 35: 1300–1306
   PubMed Web of Science ®Google Scholar
• Goldberg, R. J., M. B. Urowitz, D. Ibanez, et al. 2009. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J. Rheumatol. 36: 2454–2461
   PubMed Web of Science ®Google Scholar
• Ronnblom, L., M. L. Eloranta, and G. V. Alm. 2006. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 54: 408–420
   PubMed Web of Science ®Google Scholar
• Ronnblom, L., G. V. Alm, and M. L. Eloranta. 2011. The type I interferon system in the development of lupus. Semin. Immunol. 23: 113–121
   PubMed Web of Science ®Google Scholar
• Kaplan, M. J. (2009. Premature vascular damage in systemic lupus erythematosus. Autoimmunity 42: 580–586
   PubMed Web of Science ®Google Scholar
• Lood, C., S. Amisten, B. Gullstrand, et al. 2010. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 116: 1951–1957
   PubMed Web of Science ®Google Scholar
• Hojs, R., S. Bevc, R. Ekart, et al. 2006. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol. Dial. Transplant. 21: 1855–1862
   PubMed Web of Science ®Google Scholar
• Go, A. S., G. M. Chertow, D. Fan, et al. 2004. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351: 1296–1305
   PubMed Web of Science ®Google Scholar
• Taglieri, N., W. Koenig, and J. C. Kaski. 2009. Cystatin C and cardiovascular risk. Clin. Chem. 55: 1932–1943
   PubMed Web of Science ®Google Scholar
• Shlipak, M. G., M. J. Sarnak, R. Katz, et al. 2005. Cystatin C and the risk of death and cardiovascular events among elderly persons. N. Engl. J. Med. 352: 2049–2060
   PubMed Web of Science ®Google Scholar
• Shlipak, M. G., R. Katz, M. J. Sarnak, et al. 2006. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann. Intern. Med. 145: 237–246
   PubMed Web of Science ®Google Scholar
• Shlipak, M. G., R. Katz, M. Cushman, et al. 2005. Cystatin-C and inflammatory markers in the ambulatory elderly. Am. J. Med. 118: 1416
   PubMedGoogle Scholar
• Singh, D., M. A. Whooley, J. H. Ix, et al. 2007. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol. Dial. Transplant. 22: 1087–1092
   PubMed Web of Science ®Google Scholar
• Backlund, A., M. Holmdahl, R. Mattsson, et al. 2011. Cystatin C influences the autoimmune but not inflammatory response to cartilage type II collagen leading to chronic arthritis development. Arthritis Res. Ther. 13: R54
   Google Scholar
• Wang, J., A. S. Sim, X. L. Wang, et al. 2008. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis 197: 853–859
   PubMedGoogle Scholar
• Lertnawapan, R., A. Bian, Y. H. Rho, et al. 2011. Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus. Lupus 21: 279--287
   PubMedGoogle Scholar
• Miyakis, S., M. D. Lockshin, T. Atsumi, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4: 295–306
   PubMed Web of Science ®Google Scholar
• Galli, M., D. Luciani, G. Bertolini, and T. Barbui. 2003. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101: 1827–1832
   PubMed Web of Science ®Google Scholar
• Vikerfors A. J. A., J. T. Gustafsson, A. Jönsen, et al. (2012). Clinical manifestations and aPLs in 712 patients with SLE: evaluation of two diagnostic assays. Rheumatology, 52: 501--509
   Google Scholar
• McNeil, H. P., R. J. Simpson, C. N. Chesterman, and S. A. Krilis. 1990. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA 87: 4120–4124
   PubMed Web of Science ®Google Scholar
• Koskenmies, S., O. Vaarala, E. Widen, et al. 2004. The association of antibodies to cardiolipin, beta 2-glycoprotein I, prothrombin, and oxidized low-density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus. Scand. J. Rheumatol. 33: 246–252
   PubMed Web of Science ®Google Scholar
• Kaiser, R., C. M. Cleveland, and L. A. Criswell. 2009. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann. Rheum. Dis. 68: 238–241
   PubMed Web of Science ®Google Scholar
• Burgos, P. I., G. McGwin, Jr J. D. Reveille, et al. 2010. Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatology (Oxford) 49: 1720–1725
   PubMed Web of Science ®Google Scholar
• Meroni, P. L., F. Peyvandi, L. Foco, et al. 2007. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J. Thromb. Haemost. 5: 2421–2428
   PubMedGoogle Scholar
• de Laat, B., P. G. de Groot, R. H. Derksen, et al. 2009. Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood 114: 3656–3661
   PubMedGoogle Scholar
• Lundstrom, E., J. T. Gustafsson, A. Jonsen, et al. 2012. HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann. Rheum. Dis. 72: 1018--1025
   PubMedGoogle Scholar
• Romero-Diaz, J., F. Vargas-Vorackova, E. Kimura-Hayama, et al. 2011. Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology (Oxford) 51: 110--119
   PubMedGoogle Scholar
• Lopez, L. R., M. Salazar-Paramo, C. Palafox-Sanchez, et al. 2006. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 15: 80–86
   PubMed Web of Science ®Google Scholar
• Petri, M. 2004. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb. Res. 114: 593–595
   PubMed Web of Science ®Google Scholar
• Graham, R. R., W. Ortmann, P. Rodine, et al. 2007. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur. J. Hum. Genet. 15: 823–830
   PubMed Web of Science ®Google Scholar
• Galeazzi, M., G. D. Sebastiani, A. Tincani, et al. 2000. HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 9: 47–55
   PubMedGoogle Scholar
• Asherson, R. A., D. G. Doherty, D. Vergani, et al. 1992. Major histocompatibility complex associations with primary antiphospholipid syndrome. Arthritis Rheum. 35: 124–125
   PubMedGoogle Scholar
• Hom, G., R. R. Graham, B. Modrek, et al. 2008. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med. 358: 900–909
   PubMed Web of Science ®Google Scholar
• Remmers, E. F., R. M. Plenge, A. T. Lee, et al. 2007. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357: 977–986
   PubMed Web of Science ®Google Scholar
• Taylor, K. E., E. F. Remmers, A. T. Lee, et al. 2008. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet. 4: e1000084
   PubMed Web of Science ®Google Scholar
• Sigurdsson, S., G. Nordmark, S. Garnier, et al. 2008. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum. Mol. Genet. 17: 2868–2876
   PubMed Web of Science ®Google Scholar
• Horita, T., T. Atsumi, N. Yoshida, et al. 2009. STAT4 single nucleotide polymorphism, rs7574865 G/T, as a risk for antiphospholipid syndrome. Ann. Rheum. Dis. 68: 1366–1367
   PubMedGoogle Scholar
• Garred, P., J. Strom, L. Quist, et al. 2003. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J. Infect. Dis. 188: 1394–1403
   PubMed Web of Science ®Google Scholar
• Monticielo, O. A., T. Mucenic, R. M. Xavier, et al. 2008. The role of mannose-binding lectin in systemic lupus erythematosus. Clin. Rheumatol. 27: 413–419
   PubMedGoogle Scholar
• Garred, P., H. O. Madsen, P. Halberg, et al. 1999. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum. 42: 2145–2152
   PubMed Web of Science ®Google Scholar
• Piao, W., C. C. Liu, A. H. Kao, et al. 2007. Mannose-binding lectin is a disease-modifying factor in North American patients with systemic lupus erythematosus. J. Rheumatol. 34: 1506–1513
   PubMed Web of Science ®Google Scholar
• Madsen, H. O., V. Videm, A. Svejgaard, et al. 1998. Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet 352: 959–960
   PubMed Web of Science ®Google Scholar
• Ohlenschlaeger, T., P. Garred, H. O. Madsen, and S. Jacobsen. 2004. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N. Engl. J. Med. 351: 260–267
   PubMed Web of Science ®Google Scholar
• Font, J., M. Ramos-Casals, P. Brito-Zeron, et al. 2007. Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 46: 76–80
   PubMedGoogle Scholar
• Troelsen, L. N., P. Garred, B. Christiansen, et al. 2010. Genetically determined serum levels of mannose-binding lectin correlate negatively with common carotid intima-media thickness in systemic lupus erythematosus. J. Rheumatol. 37: 1815–1821
   PubMedGoogle Scholar
• Calvo-Alen, J., G. S. Alarcon, M. B. Tew, et al. 2006. Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. Arthritis Rheum. 54: 1940–1945
   PubMedGoogle Scholar
• Karassa, F. B., M. Bijl, K. A. Davies, et al. 2003. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum. 48: 1930–1938
   PubMed Web of Science ®Google Scholar
• Szalai, A. J., G. S. Alarcon, J. Calvo-Alen, et al. 2005. Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) 44: 864–868
   PubMed Web of Science ®Google Scholar
• Souverein, P. C., A. Berard, T. P. Van Staa, et al. 2004. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 90: 859–865
   PubMed Web of Science ®Google Scholar
• Bessant, R., R. Duncan, G. Ambler, et al. 2006. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum. 55: 892–899
   PubMedGoogle Scholar
• Jung, H., R. Bobba, J. Su, et al. 2010. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 62: 863–868
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza, G., M. V. Egurbide, J. I. Pijoan, et al. 2006. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15: 577–583
   PubMed Web of Science ®Google Scholar
• Johansson, E., K. Forsberg, and H. Johnsson. 1981. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 10: 89–96
   PubMedGoogle Scholar
• Rahman, P., D. D. Gladman, M. B. Urowitz, et al. 1999. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J. Rheumatol. 26: 325–330
   PubMed Web of Science ®Google Scholar
• Nived, O., A. Jonsen, A. A. Bengtsson, et al. 2002. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J. Rheumatol. 29: 1398–1400
   PubMed Web of Science ®Google Scholar
• Nossent, J., N. Cikes, E. Kiss, et al. 2007. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus 16: 309–317
   PubMed Web of Science ®Google Scholar
• Manger, K., B. Manger, R. Repp, et al. 2002. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann. Rheum. Dis. 61: 1065–1070
   PubMed Web of Science ®Google Scholar
• Jacobsen, S., J. Petersen, S. Ullman, et al. 1998. A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clin. Rheumatol. 17: 468–477
   PubMed Web of Science ®Google Scholar
• Faurschou, M., L. Mellemkjaer, H. Starklint, et al. 2011. High risk of ischemic heart disease in patients with lupus nephritis. J. Rheumatol. 38: 2400--2405
   PubMed Web of Science ®Google Scholar
• Zhang, W., E. Aghdassi, H. N. Reich, et al. 2010. Glomerular filtration rate predicts arterial events in women with systemic lupus erythematosus. Rheumatology (Oxford) 799: 799--805
   Google Scholar
• Falaschi, F., A. Ravelli, A. Martignoni, et al. 2000. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 43: 1405–1409
   PubMedGoogle Scholar
• Schanberg, L. E., C. Sandborg, H. X. Barnhart, et al. 2009. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum. 60: 1496–1507
   PubMed Web of Science ®Google Scholar
• Souza, A. W., F. S. Hatta, F. Miranda, Jrand E. I. Sato. 2005. Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Med. J. 123: 137–142
   PubMedGoogle Scholar
• Roman, M. J., R. B. Devereux, J. E. Schwartz, et al. 2005. Arterial stiffness in chronic inflammatory diseases. Hypertension 46: 194–199
   PubMed Web of Science ®Google Scholar
• Jimenez, S., M. A. Garcia-Criado, D. Tassies, et al. 2005. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 44: 756–761
   PubMedGoogle Scholar
• Von Feldt, J. M., L. V. Scalzi, A. J. Cucchiara, et al. 2006. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum. 54: 2220–2227
   PubMed Web of Science ®Google Scholar
• Chung, C. P., A. Oeser, I. Avalos, et al. 2006. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 15: 562–569
   PubMed Web of Science ®Google Scholar
• Gallelli, B., L. Burdick, S. Quaglini, et al. 2010. Carotid plaques in patients with long-term lupus nephritis. Clin. Exp. Rheumatol. 28: 386–392
   PubMedGoogle Scholar
• Gustafsson J. T., K. Urstad-Jensen, M. Herlitz-Lindberg, et al. 2013. Occurrence and associations of atherosclerosis in systemic lupus erythematosus: a cross-sectional study of 281 patients with matched population controls. Lupus 22: 79(Poster 124)
   Google Scholar